证券代码：688382 证券简称：益方生物 公告编号：2025-015 益方生物科技（上海）股份有限公司 第二届董事会 2025 年第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"或"益方生物"） 第二届董事会 2025 年第二次会议于 2025 年 4 月 25 日以现场结合通讯形式召开， 本次会议通知已于 2025 年 4 月 15 日以书面等形式发出。会议应出席董事 9 名， 实际出席董事 9 名，公司监事及高级管理人员列席本次会议。本次会议的召集、 召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"）及《益方生 物科技（上海）股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 公司董事长 YAOLIN WANG（王耀林）先生召集并主持本次会议。 二、董事会会议审议情况 出席会议的董事审议通过以下议案： （一）审议通过《关于 2024 年度总经理工作报告的议案》 表决结果：同意 9 票；反对 0 票；弃权 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-019 益方生物科技（上海）股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案的具体内容 经立信会计师事务所（特殊普通合伙）审计，公司 2024 年度归属于上市公 司股东的净利润为-24,020.38 万元，母公司净利润为-12,007.84 万元；截至 2024 年 12 月 31 日，母公司累计未分配利润为-90,646.22 万元。为保障和满足公司正 常经营和持续发展需要，根据《科创板股票上市规则》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》及《公司章程》等的有关规定， 经董事会决议，公司 2024 年度利润分配方案为：不派发现金红利，不送红股， 不以资本公积金转增股本。本议案尚需提交公司股东大会审议。 （二）是否可能触及其他风险警示情形 本次利润分配方案不会触及《科创板股票上市规则》第 12.9.1 条第一款第 （八）项规 ...

前十大流通股东累计持有： 13644.76万股，累计占流通股比： 34.13%，较上期变化： -1252.14万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | ABA-Bio (Hong Kong) Limited | 3294.00 | 8.24 | 不变 | | LAV Apex Hong Kong Limited | 2407.92 | 6.02 | 不变 | | OAP III (HK) Limited | 1992.93 | 4.99 | 不变 | | HH SPR-XIV HK Holdings Limited | 1257.67 | 3.15 | -721.74 | | LAV Alpha Hong Kong Limited | 1203.96 | 3.01 | 不变 | | 博山投资有限公司 | 936.22 | 2.34 | 不变 | | 中欧医疗健康混合A | 671.60 | 1.68 | 新进 | | 鹏华医药科技股票A | 666.75 | 1.67 | 不变 | | Sunflower ...

关于益方生物科技（上海）股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 2、 附表 委托单位：益方生物科技（上海）股份有限公司 审计单位：立信会计师事务所（特殊普通合伙） 联系电话：021-23280000 益方生物科技（上海）股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 目 录 1、 专项审计报告 2024 年度 关于益方生物科技（上海）股份有限公司 非经营性资金占用及其他关联资金往来情况 信会师报字[2025]第 ZA11565 号 益方生物科技（上海）股份有限公司全体股东： 我们审计 物")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 25 日出具了报告号为信会师报字[2025]第 ZA11562 号的 无保留意见审计报告。 益方生物管理层根据中国证券监督管理委员会《上市公司监管 指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和上海证券交易所《科创板上市公司自律监管 指南第 7 号——年度报告相关 ...

益方生物科技(上海)股份有限公司 募集资金存放与使用情况 专项报告的鉴证报告 2024年度 您可使用手机"扫一扫" 此码用于证明该审计报告是否由具有执业许可的会计师事务 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"为 the with the first of the country of the country of the support of 2018 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 益方生物董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告〔2022〕15号)、《上海证券交易所 科创板上市公司自律监管指引第1号 -- 规范运作》以及《上海证券 交易所上市公司自律监管指南第1号 -- 公告格式》的相关规定编制 募集资金专项报告。这种责任包括设计、执行和维护与募集资金专项 报告编制相关的内部控制,确保募集资金专项报告真实、准确、完整, 不存在虚假 ...

益方生物科技(上海)股份有限公司 审计报告及财务报表 二〇二四年度 iiE明该审计报告是否由具有执业许可的会计师行业统一些 您可使用手机"扫一扫"或进入"注册会 益方生物科技(上海)股份有限公司 审计报告及财务报表 (2024年01月01日至2024年12月31日止) | 目录 | 页次 | | --- | --- | | 审计报告 | 1-4 | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-87 | 审计报告 第1页 Í I I 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LI 审计 报告 信会师报字[2025]第 ZA11562 号 益方牛物科技(上海)股份有限公司全体股东: 一、审计意见 我们审计了益方生物科技(上海)股份有限公司(以下简称益方 生物)财务报表,包括2024年12月31日的合并 ...

益方生物科技(上海)股份有限公司 内部控制审计报告 2024 年 12 月 31 日 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 内部控制审计报告 信会师报字[2025]第 ZA11563 号 益方生物科技(上海)股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了益方生物科技(上海)股份有限公司(以下简称 益方生物）2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是益方生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的 有效性发表审计意见,并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和 ...

中信证券股份有限公司关于 益方生物科技（上海）股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为益方 生物科技（上海）股份有限公司（以下简称"益方生物"或"公司"）首次公 开发行的保荐人，根据《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等有关规定，对益方生物 2024 年度募集资金的存放和使用情况进 行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生 物科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可（2022） 682 号），公司获准向社会公开发行人民币普通股 11,500 万股，每股发行价格 为人民币 18.12 元，募集资金总额为 208,380.00 万元，扣除承销及保荐费用、 发行登记费以及累计发生的其他相关发行费用（共计人民币 101,646,630.18 元， 不含税）后，募集资金净额为 1,9 ...

Financial Performance - The net loss attributable to shareholders for the year 2024 was CNY 240.20 million, with a net loss of CNY 250.14 million after deducting non-recurring gains and losses, showing a reduction compared to the same period last year [4]. - The cumulative unabsorbed losses as of the end of the reporting period amounted to CNY 2,544.93 million [4]. - The company's revenue for 2024 was CNY 168.79 million, a decrease of 9.02% compared to CNY 185.53 million in 2023 [27]. - The net loss attributable to shareholders for 2024 was CNY 240.20 million, improving from a loss of CNY 283.98 million in 2023 [27]. - The basic earnings per share for 2024 was -CNY 0.42, compared to -CNY 0.49 in 2023 [28]. - The total assets decreased by 11.17% from CNY 216.23 million in 2023 to CNY 192.08 million in 2024 [27]. - The net assets attributable to shareholders at the end of 2024 were CNY 181.08 million, a decrease of 9.35% from CNY 199.76 million in 2023 [27]. - The cash flow from operating activities for 2024 was -CNY 241.97 million, compared to -CNY 307.75 million in 2023 [27]. - The company's total sales revenue for the year reached 168.79 million RMB, with the top five customers accounting for 100% of this total [163]. - The largest customer contributed 90.30% of the total sales, amounting to 152.41 million RMB, while the second largest customer accounted for 9.70% with sales of 1.64 million RMB [164]. Research and Development (R&D) - The company plans to maintain a high level of R&D investment to support multiple ongoing projects, despite the risk of continued losses [5]. - The company's R&D expenditure as a percentage of revenue was 227.71% in 2024, down from 238.73% in 2023, a reduction of 11.02 percentage points [28]. - The company maintained a high level of R&D investment at 384.35 million yuan in 2024 [40]. - The company has established a comprehensive R&D system covering drug discovery, preclinical research, clinical trials, and regulatory affairs, ensuring a robust pipeline of clinical candidates [63]. - The company has established R&D centers in Shanghai, Beijing, and the United States, enhancing its global competitiveness and innovation capabilities [133]. - The R&D team consists of 169 members, accounting for 91.35% of total employees, with significant expertise in drug development, including 19 PhDs and 64 Master's degrees [138]. - The company’s R&D investment as a percentage of total assets is 21.23%, indicating a strong focus on innovation [183]. - The average R&D investment among comparable companies in the industry is 68,033.73 million RMB, highlighting the company's significant commitment to R&D [183]. Product Pipeline and Clinical Trials - The company has two authorized products, Beifu Tini and Gesorase, which have been launched, and expects to receive milestone payments and sales sharing as clinical research and commercialization progress [5]. - The company has not yet established a commercial sales team, which may impact the market acceptance of its products post-approval [145]. - The company has five clinical products, with two already approved for market, while three are in clinical trial stages [176]. - The company is focusing on developing multiple preclinical pipelines in areas such as kinase, tumor driver genes, tumor immunity, and synthetic lethality pathways [176]. - The company’s clinical pipeline includes drugs targeting unmet medical needs, with a focus on oncology and autoimmune diseases [132]. - D-0502, an oral selective estrogen receptor degrader (SERD), is in Phase III clinical trials for ER-positive, HER2-negative breast cancer, with the first patient enrolled in September 2022 [42]. - D-0120, a URAT1 inhibitor for hyperuricemia and gout, has completed multiple Phase I trials and is currently in a Phase II trial in China, expected to complete by November 2024 [42]. - D-2570, a novel oral selective TYK2 inhibitor for psoriasis, started Phase II clinical trials in December 2023, showing significant efficacy compared to placebo and existing TYK2 inhibitors [43]. - The company has made significant progress in clinical research for its main products in 2024 [40]. - The product Gexorese (Anfangning®) received approval from the National Medical Products Administration (NMPA) in November 2024 [40]. - The product Beifu Tini (BPI-D0316) received NMPA approval for its second-line treatment indication in December 2023 and for its first-line treatment indication in November 2024 [41]. Market and Competitive Landscape - The global pharmaceutical market grew from $1,266.7 billion in 2018 to $1,495.0 billion in 2022, with a CAGR of 4.2% from 2018 to 2022 [70]. - In 2022, the Chinese pharmaceutical market reached ¥1,554.1 billion, with projected CAGR of 8.1% from 2022 to 2025 and 6.0% from 2025 to 2030 [73]. - The global anti-tumor drug market increased from $110.6 billion in 2017 to $181.7 billion in 2021, with a CAGR of 13.2% [79]. - China's anti-tumor drug market grew from ¥139.4 billion in 2017 to ¥231.1 billion in 2021, with a CAGR of 13.5% [79]. - The global metabolic disease market expanded from $105.0 billion in 2018 to $160.0 billion in 2022, with a CAGR of 10.9% [82]. - The global autoimmune disease drug market was approximately $132.3 billion in 2022, expected to reach $147.3 billion by 2025, with a CAGR of 3.6% from 2022 to 2025 [93]. - The Chinese autoimmune disease drug market was about $2.9 billion in 2022, projected to grow to $6.1 billion by 2025, reflecting a CAGR of 27.4% [93]. Risks and Challenges - The company faces significant risks in drug development, including long cycles and high investment requirements, which may lead to substantial performance declines or losses [5]. - The company has not established a complete commercialization and sales team, which may hinder market acceptance of its products [8]. - The company relies on third-party CMO for production, which introduces risks related to supply and quality control [8]. - The company emphasizes the uncertainty of entering the National Medical Insurance Directory, which could impact the pricing competitiveness of its products [8]. - The company is currently not profitable, with ongoing R&D investments and cumulative losses, relying on milestone payments and sales shares from its two approved products to improve financial conditions [141]. - The company faces risks related to significant financial investments in drug development, potential competition from established players, and uncertainties in market acceptance and reimbursement for its products [145]. Corporate Governance - The company held one annual and one temporary shareholders' meeting during the reporting period, ensuring compliance with relevant laws and regulations [198]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period to review all proposals [198]. - The annual general meeting held on June 21, 2024, approved 8 resolutions without any being rejected [200]. - The first extraordinary general meeting of 2024 took place on September 9, 2024, where 2 resolutions were approved without any rejections [200]. - All resolutions discussed in the shareholder meetings complied with relevant laws and regulations [200].

益方生物科技（上海）股份有限公司 独立董事 2024 年度述职报告 本人作为益方生物科技（上海）股份有限公司（以下简称"公司"或"益方生 物"）第一届董事会和第二届董事会独立董事，严格按照《公司法》《证券法》《上 市公司独立董事管理办法》等有关法律法规、规范性文件的要求以及《公司章程》 等相关制度，忠实、勤勉、尽责地履行独立董事职责，维护公司整体利益和全体 股东尤其是中小股东的合法权益，较好地发挥了独立董事的作用。现将 2024 年 度履职情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 WEN CHEN（陈文），1968 年生，美国国籍，毕业于美国圣路易华盛顿大学 医学院生物学及生物医学专业、英国杜伦大学商学院工商管理专业，研究生学历。 1997 年至 2009 年，曾先后任职于美国安进公司、中药通医药科技（成都）有限 公司、上海单抗制药技术有限公司、上海华谊生物技术有限公司、美国沪亚生物 技术有限公司上海代表处以及辉源生物科技（上海）有限公司；2009 年至 2020 年，于杭州泰格医药科技股份有限公司任资深副总裁；2020 年至今，于上海涌 铧投资管理有限公司任生物医药投资 ...